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Laboratory measurement of the quantity of creatine and preformed creatinine
excreted in the urine is of diagnostic value to the clinician only when interpreted
in the light of the clinical findings. Even then its significance is of questionable
importance, as creatinuria occurs in many diseased states, under certain physi—
ologic and dietary conditions, and after the administration of certain drugs. It
occurred to us that determinations of the amount of creatine and creatinine
excreted in the urine of patients who had dermatomyositis were being done with-
out adequate evaluation. Therefore, we decided to analyze our accumulated data
in order to ascertain the value of these measurements in the diagnosis, course
and prognosis of this disease.
SYNTHESIS AND METABOLISM OF CREATINE
The significance of excretion of abnormal amounts of creatine and creatinine
in the urine can be better understood when the basic principles involved in the
synthesis and metabolism of these substances are known. Actually, knowledge of
metabolism of creatine is far from complete, but substantial progress has been
made since the announcement in 1927 of the discovery of phosphocreatine in
muscle by Fiske and Subbarow (1) and the publication of a monograph on crea-
tine and creatinine by Hunter (2) in 1928. Borsook and associates (3) showed
that glycocyamine (guanidoacetic acid), a precursor of creatine, can be formed
from glycine and arginine by slices of surviving kidneys of experimental animals.
They (4) also showed that simultaneous administration of glycine and arginine
in man results in synthesis of glycocyamine, as judged by the appearance of sig-
nificantly increased amounts of the compound in the urine. Conversion of glyco-
cyamine to creatine by methylation in the presence of methionine occurs in
slices of surviving liver, and Du Vigneaud and co-workers (5) demonstrated the
transfer of the methyl group of methionine to glycocyamine in intact animals
by means of feeding methionine labeled with deuterium in the methyl group.
In man, observations of Sandberg's group (6) suggested that the main site of
synthesis of creatine and its precursors is the liver, the renal production of glyco-
cyamine being insufficient to account for the large amounts of creatine coming
from the liver.
The chief depot of creatine in the body is the voluntary skeletal muscle, where
it exists largely in the form of phosphocreatine (7) and from which it escapes into
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Fia. 1. Synthesis of creatine and creatinine as modified from figure 58 (page 914) of Peters
and Van Slyke (10).
(a) Creatine is excreted in the urine if plasma concentration exceeds 0.58 mg. per 100 ml.
(b) 2% of creatine phosphate is converted to creatinine daily and is excreted in the urine.
the urine under normal conditions only in the form of its anhydride, creatinine.
According to studies of Bloch and associates (8), in which the body creatine of
animals was labeled with isotopic nitrogen (N15), creatine is the only source of
creatinine, and the rate of conversion is relatively constant at about 2 per cent
of total body creatine per day. In a human, Hoberman and associates (9)
noted that 1.64 per cent of the stored creatine was excreted as creatinine per
day. Pathologic creatinuria in humans exists when more than 50 to 60 mg. of
creatine appears in the urine in 24 hours under ordinary conditions of activity
and diet or when more than 30 per cent of an ingested dose of 1.32 gm. of crea-
tine, equivalent to 1.0 gm. of creatinine, is excreted in the ensuing 24 hours (10).
Diagrammatic representation of some of these relationships is presented in
figure 1.
PRESENT STUDY
Data on the excretion of creatine and creatinine have been obtained from a
large number of patients with dermatomyositis seen at the Mayo Clinic since
1937 (11, 12). In confirmation of previous reports (13, 14), it was found that
many of these patients excreted considerable quantities of creatine in the urine.
Prior to 1946, the urinary creatine and creatinine were determined according to
the method of Folin (15); since then, the method has been that of Bonsnes and
Taussky (16), except that creatine was converted to creatinine by hydrolysis in
an autoclave. In a majority of instances, the test was performed on hospitalized
patients who received a balanced diet consisting of 75 gm. of protein, 190 gm.
of carbohydrate and 135 gm. of fat. All were studied in the postabsorptive state
(12 hours after a meat-free meal). Only those patients in whom the total volume
of urine excreted in a 24-hour period was equal to or in excess of 1,000 ml. were
included in this survey.
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TABLE 1
Urinary excretion of creatine and creatinine in dermatomyositis: 134 cases
Groups a
tients
Pa-
tients,
no.
and
sex
Urinary creatine, mg./24 hrs. Preformed creatinine, mg./24 hrs.
Range
Average
M F M--F Range
Average
M F M+F
15 years of age or 25 F: 16 170—2,090 704 391 547 116—1,355 633 368 501
less M:9
Morethanl5years 109 F:82 202—2,796 540 458 499 200—1,952 881 774 827
of age M:27
All ages 134 F: 98 170—2,796 622 424 523 116—1,952 757 571 664
M: 36
Patients with as- 7 F: 6 112—690 — — 400 374—1,446 — 778
sociated car- M: 1
cinoma
We reviewed the case records of 270 patients with dermatomyositis. This
group included 179 females and 91 males; the ages ranged from 23z to 73 years.
Determinations of creatine and creatinine were obtained on 134 patients, 98
females and 36 males. Single determinations were obtained in 89 instances and
multiple determinations (three or more) in 45. For comparison, a survey was
made of 27 patients with diseases other than dermatomyositis, such as sclero-
derma and systemic lupus erythematosus.
RESULTS
The values of creatine and preformed creatinine for the 134 patients who had
dermatomyositis are summarized in table II. In the younger age group (15 years
of age or less), a 15-year-old boy with acute dermatomyositis from which he died
3 months later excreted the most creatine (2,090 mg. in 24 hours). This patient
excreted 674 mg. of preformed creatinine in 24 hours. In the older age group
(more than 15 years of age), a 49-year-old woman with severe acute dermatomyo-
sitis excreted the largest amount of creatine (2,796 mg. in 24 hours), with a cor-
responding excretion of creatinine of 565 mg. The values for patients who had
dermatomyositis complicated by carcinoma are included in table 1. This group
consisted of six women and one man, whose ages ranged from 40 to 71 years.
The values of creatine and creatinine in the 27 patients with diseases other
than dermatomyositis are summarized in table 2. The ages of the 11 patients with
generalized scleroderma ranged from 25 to 61 years; the six patients with systemic
lupus erythematosus ranged from 24 to 35 years of age; the man with rheumatoid
arthritis was 56; the two men with fibromyositis (diffuse myositis) were 62 and
66; the man and the woman who had muscular dystrophy were 56 and 20 years
of age, respectively; the man with amyotrophic lateral sclerosis was 62. The con-
dition in the three patients with severe dermatitis medicamentosa was due to
penicillin, acetylsalicylic acid (aspirin) and quinacrine hydrochloride (atabrine),
respectively; their ages ranged from 36 to 62 years. The woman who had pemphi-
gus vulgaris was 40 years of age.
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TABLE 2
Urinary excretion of creatine and creatinine in diseases other than dermatomyositis: 27 cases
.Disease
No.
of
tients
.Patients,
no. and
sex
Urinary creatine,
mg./24 hrs.
Urinary preformed rreatinine,
mg./24 hrs.
Range Average Range Average
Generalized scieroderma 11 F: 10 44—620 378 550—1,153 857
M:1
Systemic lupus erythema- 6 F: 5 56—715 324 733—1,652 1,041
tosus M: 1
Rheumatoid arthritis 1 M — 884 — 1,270
Fibromyositis 2 M 329—500 414 1,243—1,366 1,304
Dermatitis medicamentosa 3 F: 1 48-906 676 993—1,662 1,386
M: 2
Pemphigus vulgaris 1 F — 680 — 1,116
Muscular dystrophy 2 F: 1 — 582 — 600
M: 1
Amyotrophic lateral 1 M — 0 — 1,008
sclerosis
TABLE 3
Dermatontyositis: case 1
Urinary Urinary preformed
Date creatine, creatinine,
rng./24 hrs. mg./24 hrs.
Pretreatment values 5/1/53 370 773
Cortisone, 25 mg./24 hrs. 5/13/53 — —
1 month after beginning cortisone 6/8/53 480 320
6 months after beginning cortisone 11/27/53 386 320
The following cases of dermatomyositis are reported to illustrate the excretion
of ereatine and creatinine in the various phases of the disease.
REI'OIIT OF CASES
Case 1—A 5-year-old boy with subacute dermatomyositis of 2 years' duration was
treated with cortisone and obtained a remission. At his last visit, which was in August, 1955,
he was in relatively good condition (active and afebrile) except for moderate calcinosis and
minimal muscular atrophy. Use of cortisone was discontinued at that time.
Comment—The excretion of creatine was increased and remained so even after small
doses (25 mg. daily) of cortisone had been administered and despite clinical improvement
(table 3). The excretion of creatinine continued to be decreased throughout the period of
observation.
Case 2—A 6-year-old girl with subacute to chronic dermatomyositis of 10 months' dura-
tion was treated symptomatically and obtained a remission. At the time of our last corre-
spondence (July, 1953), she was active, hut osteoporosis, calcinosis and moderate atrophy of
the proximal muscles, with contracturcs, had developed.
Connnent.—The excretion of creatine remained increased during the year that the child
was under observation (table 4). Administration of vitamin E had no appreciable effect on
the excretion of creatine or on the clinical course of the disease. The excretion of creatinine
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TABLE 4
Dermatomyositis: case 2
Date Urinary creatine,
mg./24 hrs.
Urinary preformed
creatinine, mg./24 hrs.
Vitamin E, 100 mg./24 hrs.,
and physiotherapy
6/19/49
6/29/49
6/3/50
406
379
500
310
296
179
TABLE 5
Dermatomyositis: case 3
Date Urinary creatine,
mg./24 hrs.
Urinary preformed
creatinine, mg./24 hrs.
Symptomatic treatment 10/22/41
10/27/41
11/3/41
11/6/41
11/12/41
591
1,880
695
751
1,041
800
880
766
855
832
Death 11/14/41 — —
was greatly decreased, more so than in case 1 because of the increased amount of muscular
atrophy and fibrosis.
Case 3.—A 19-year-old boy had acute dermatomyositis of 4 months' duration. He died 1
month after admission. His weight was 160 pounds on admission; he had lost 35 pounds.
Comment—The excretion of creatine was greatly increased and variable, whereas the
excretion of creatinine was only slightly decreased and constant (table 5).
Case 4.—A 17-year-old girl with subacute dermatomyositis of 10 months' duration was
treated with cortisone and obtained a remission. The disease subsequently became chronic
and was characterized by pronounced atrophy, fibrosis and contractures of muscles but she
was able to be up and about. She was last examined in January, 1955, which was 6 years
after onset of the disease and after 5 years of administration of cortisone.
Comment—This patient was seen frequently for 5 years, during which administration of
cortisone was continuous (75 mg. or less per 24 hours). During this entire time, the excretion
of creatine in the urine was increased and variable, whereas that of creatinine gradually
decreased to a stable level (table 6). The decreased excretion of creatinine was in direct
proportion to the degree of muscular atrophy and fibrosis (total amount of efficiently func-
tioning muscle).
Case 5.—A 34-year-old man with subacute dermatomyositis of 7 months' duration was
treated with cortisone and obtained a remission that was followed by a mild relapse, a
second remission and then recovery.
Comment—The administration of cortisone in doses of 100 mg. per 24 hours had no appre-
ciable effect on the excretion of creatine or creatinine (table 7). Use of 200 mg. of cortisone
daily likewise had no appreciable effect on the excretion of these two substances when the
patient clinically had manifested no signs of improvement, but excretion of creatine
increased when administration of the drug was discontinued. After readministration of
cortisone (200 mg. daily), during which the patient manifested signs of improvement (re-
mission), excretion of creatine was greatly decreased temporarily and that of creatinine
also was decreased slightly. Excretion of both constituents increased after administration
of cortisone was discontinued despite the fact that a clinical remission was maintained.
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TABLE 6
Derrnatornyosilis: case 4
Date
Urinary
creatine,
rng./24 hrs.
Urinary pre-
formed creatinine,
mg./24 hrs.
Pretreatment values
Cortisone, 75 mg./24 hrs.
3 weeks after beginning cortisone
Cortisone discontinued
Cortisone resumed, 75 mg./24 hrs.
1 week after cortisone resumed
3) years later (cortisone, 62.5 mg./24 hrs.)
43 years later (cortisone, 50 mg./24 hrs.)
11/3/49
11/8/49
11/30/49
12/16/49
12/25/49
12/28/49
1/27/50
2/3/50
10/21/53
11/3/53
5/4/54
9/9/54
1,022
—
1,284
—
781
701
—
714
629
851
1,076
789
828
—
762
—
489
520
—
588
578
541
586
576
TABLE 7
Dermatomyositis: case 5
Date
Urinary
creatine,
mg./24 hrs.
Urinary pre-
formed creatinine,
mg./24 hrs.
Cortisone, 100 mg./24 hrs. (1.M.) 11/2/49 — —
11/9/49 214 841
11/15/49 370 762
Cortisone, 200 mg./24 hrs. (1.M.); total = 11/16/49 — —
2,800 mg. 11/22/49 388 757
Cortisone discontinued 11/24/49 —
12/5/49 812 775
12/22/49 742 896
Unimproved 1/24/50 774 919
Cortisone, 200 mg./24 hrs. (I.M.); total = 1/27/50 — —
2,800 mg. 2/2/50 260 773
2/8/50 97 487
Cortisone discontinued 2/9/50 —
Improving 2/26/50 819 1,001
5/25/50 492 820
12/1/50 321 759
Case 6.—A 26-year-old woman with acute dermatomyositis of 4 months' duration was
treated with cortisone and methyltestosterone; she obtained a remission and maintained it
to recovery. When last examined, in December, 1953, her contlition was good except for
moderate muscular atrophy.
Comment—-The simultaneous administration of cortisone (100 mg. daily) and methyl-
testosterone (20 mg. daily) effected a great increase in the excretion of creatine but little
change in the excretion of creatinine (table 8). It is clearly demonstrated that this effect was
produced by the methyltestosterone rather than the cortisone. The excretion of creatinine
increased after treatment and the patient simultaneously improved clinically. Use of corti-
sone was discontinued on December 1, 1953, at which time the patient was improved and
active.
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TABLE 8
Dermatomyositis: case 6
Date Urinary creatine,mg./24 hrs.
Urinary preformed
creatinine, mg./24 hrs.
Pretreatment values
Cortisone, 100 mg./24 hrs.
Methyltestosterone, 20 mg./24
hrs.
5/26/53
5/31/53
6/7/53
6/17/53
6/18/53
6/27/53
7/9/53
7/21/53
527
—
455
496
—
1,111
1,181
1,955
461
—
670
748
—
998
1,156
1,060
TABLE 9
Dermetomyositis: case 7
Date Urinarycreatine,
mg./24 hrs.
Urinary pre-
formed creatinine,
mg./24 hrs.
Pretreatment values
Cortisone, 100 mg./24 hrs.
1 month after beginning cortisone
Methyltestosterone, 10 mg./24 hrs.
Methyltestosterone discontinued
Cortisone discontinued
Remission
Cortisone resumed (relapse)
3/23/53
4/1/53
5/3/53
5/18/53
6/24/53
7/15/53
10/14/53
12/15/53
1/7/54
7/23/54
1,821
—
2,032
—
2,796
—
1,946
—
391
1,799
963
—
544
—
565
—.
980
—
899
1,036
Case 7.—A 49-year-old woman with acute dermatomyositis of 8 months' duration was
treated with cortisone and methyltestosterone; dramatic improvement occurred and she
obtained a partial remission. Use of cortisone was then discontinued and a relapse took
place. Administration of cortisone was resumed, which produced a remission that has been
maintained.
Comment—The simultaneous administration of cortisone (100 mg. daily) and methyl-
testosterone (10 mg. daily) effected an increase in the excretion of creatine, as noted in
table 9. A definite remission followed treatment, during which the excretion of creatine
greatly decreased and that of creatinine increased. The patient subsequently had a relapse,
during which the excretion of creatine increased but that of creatinine remained unchanged.
At last report, in October, 1954, she felt well and was active. She was still taking cortisone.
ANALYSIS OF RESULTS
The greatest amount of creatine was excreted during the acute febrile phase
of the disease; in some instances, the amount was proportional to the severity
of the disease. Excretion of creatinine was decreased during this phase of the
disease. During a remission, whether spontaneous or induced by use of steroids,
the degree of creatinuria gradually decreased and the excretion of creatinine
gradually increased. A relapse was often followed by accentuation of creatinuria
and reduction in the excretion of creatinine to levels comparable to those of the
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initial acute phase. In the chronic phase of dermatomyositis, creatinuria con-
tinued, at times being the same as that during the acute phase, whereas the ex-
cretion of creatinine was decreased, often to a greater extent than it was during
the acute phase of the disease.
Creatinuria was increased in patients who had elevated basal metabolic rates
(more than +20 per cent), as recorded in 22 instances. Eaton (17) stated that
the basal metabolic rate gives information comparable to that derived from the
excretion of creatine in patients with polymyositis (dermatomyositis without
dermatologic manifestations). Excretion of creatine was increased in 79 of our
134 patients in whom the erythrocytic sedimentation rate (Westergren method)
was increased to more than 40 mm. during the first hour. The degree of creati-
nuria and the decrease iii excretion of creatinine varied directly with the amount
of weight lost, being greatest in those patients who had lost the most weight.
The loss of weight per patient in 41 patients exceeded 20 pounds; the average
loss for the 134 patients was 19 pounds per patient. Dysphagia was a contribu-
tory factor to the loss of weight in 69 patients.
The degree of decrease in the amount of creatinine excreted varied directly
with the total amount and degree of muscle involved by the inflammatory
process and with the decrease in the total mass of muscle that was the residual
of the disease (atrophy and fibrosis). This decrease in excretion of creatinine
appeared especially significant in muscular men during the acute edematous
phase of the disease, in which the presence of considerable "doughy" edema of
the tissues presented a more apparent than real normal muscular state. Excre-
tion of creatinine was fairly constant and stable for each patient, although it
varied from person to person and was less in children and women than it was iii
men.
In six patients, use of a low-creatine diet (meat free) for a 3-day period pre-
ceding the determinations produced no appreciable change in the excretion of
creatine and creatinine. Use of high-protein diets was not investigated and
creatine tolerance tests were not done, as we found it impractical to place these
patients in a controlled metabolic unit for study.
Cortisone given in amounts of 100 mg. or less in 24 hours produced no appre-
ciable change in the excretion of creatine or creatinine. A remission induced by
use of cortisone produced a decrease in the excretion of creatine and an increase
in that of creatinine. Methyltestosterone, when administered alone or simultane-
ously with cortisone, produced a rather pronounced increase in excretion of crea-
tine but no appreciable change in that of creatinine. Vitamin E administered to
a number of patients with dermatomyositis produced insignificant changes iii
the excretion of creatine and creatinine.
Appreciable differences were not apparent in the excretion of either substance
in uncomplicated dermatomyositis and that complicated by associated carci-
noma. Excretion of creatine was increased in all of the patients with diseases
other than dermatomyositis, with the exception of the one patient. who had
amyotrophic lateral sclerosis. This increase was comparable to that seeti in pa-
tients with dermatomyositis. The excretion of creatinine, on t.he other hand, was
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essentially normal except for decreases in the patients with scieroderma and
muscular dystrophy.
COMMENT
Creatinuria as it occurs in dermatomyositis is an extremely variable phenome-
non. The chief features of the disease related to creatinuria undoubtedly are
muscular degeneration and wasting, conditions present in other diseases, such as
progressive muscular dystrophy, associated with copious creatinuria. Other
related features include (a) loss of weight as a result of anorexia, dysphagia and
an increase in catabolism of protein; (b) fever, with a resultant increase in meta-
bolic rate and (c) immobility and inactivity.
Remission of the disease, whether spontaneous or induced by use of steroids,
is characterized by reduction in the abnormally great urinary excretion of crea-
tine. As the exact mechanism of the creatinuria is obscure, so too is the mecha-
nism of remission. Administration of cortisone may interrupt abnormal reactions
or influence defective muscular processes by decreasing inflammation or possibly
by inhibiting a reaction of hypersensitivity on the part of the host to an unknown
etiologic agent. Relapse precipitated by stress, such as intercurrent infection,
menstruation, menopause, trauma, emotional upheaval or withdrawal of steroid
therapy, is followed by reactivation of the pathologic process and an increase in
the excretion of creatine.
Urinary excretion of creatinine is reduced in all phases of dermatomyositis,
generally in direct proportion to the severity of the disease. Reduced excretion of
creatinine was most pronounced and significant in the chronic phase, especially in
those patients in whom severe fibrosis, muscular atrophy and contractures were
present. If the output of creatinine is a valid index of creatine stores and muscle
mass, as it is considered to be in normal man and animals, reduced excretion is
consistent with the obviously reduced muscle mass (and low creatine stores) in
these patients. We already have suggested that reduced musculature may, in
fact, represent the most important factor predisposing to creatinuria. Observa-
tions on progressive muscular dystrophy by Stetten's group (18—20), based on
excretion of labeled creatine after administration of glycine N15, indicated that
creatine produced in normal quantity by the liver exceeds the capacity of the
diminished musculature to accept it and, therefore, it escapes in large amounts
in the urine. Substantially the same view of the mechanism of creatinuria in
progressive muscular dystrophy was arrived at by Hoagland and associates (21),
in 1945, who stated: 'The diminished excretion of creatinine in progressive
muscular dystrophy is a more striking and specific phenomenon than the excess
excretion of creatine, marked though this is. While creatinuria is invariably
encountered in all cases of long-standing dystrophy, the extent to which the
excretion of creatinine is decreased provides a more reliable indication of the
severity of the disease since an excess output of creatiiie may occur physiologi-
cally in normal subjects and in many pathological conditions not known to be
associated with muscle disease." These cautions as to the significance of creati-
nuria in progressive muscular dystrophy are well taken, we believe, and conform
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with our opinion as to its significance in dermatomyositis. As to the mechanism
of creatinuria in the latter condition, aside from decreased muscle mass, a variety
of other defects may exist, elucidation of which must depend on the results of
further investigation.
SUMMARY AND CONCLUSIONS
A study has been made on the excretion of creatine and creatinine in the urine
of 134 patients with dermatomyositis. Similar studies were made on 27 patients
with other diseases.
The excretion of creatine is increased in dermatomyositis as well as in many
other diseases. Excretion of creatinine is decreased in dermatomyositis and in
other diseases characterized by muscular degeneration.
Determination of urinary creatine and creatinine is of questionable value in
the diagnosis and prognosis of dermatomyositis. Until more is known about the
metabolism of these substances, measurement of their excretion is of limited
help to the clinician.
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